Olav Hellebø Takes the Helm as CEO of BerGenBio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to developing novel AXL kinase inhibitors targeting severe medical needs, has appointed Olav Hellebø as its new CEO. This decision underscores the company's commitment to advancing its therapeutic innovations in the field of oncology.
Introducing Olav Hellebø
Mr. Hellebø, who takes on the CEO position, comes with a remarkable three-decade background within the pharmaceutical and biotechnology sectors. Most recently, he has served as a board director at Cytovation ASA and Antev Ltd., organizations that specialize in immuno-oncology and treatments related to urology and oncology, respectively. His comprehensive career also includes pivotal roles at ReNeuron Group PLC and Clavis Pharma ASA, where he focused on advancements in cell therapy and oncology.
Vision for BerGenBio
In his new role, Olav Hellebø has expressed his excitement about BerGenBio's cutting-edge work in exploring selective AXL inhibition. This innovative approach could significantly enhance therapeutic options for patients suffering from non-squamous non-small cell lung cancer with STK11 gene mutations. Hellebø looks forward to collaborating with the board and team, particularly to propel the candidate drug, bemcentinib, through the clinical development phases.
Strategic Directions
The Chairman of the Board, Anders Tullgren, has lauded Hellebø's extensive leadership experience, emphasizing his proven track record in managing biotech firms and establishing successful partnerships. Tullgren noted that Hellebø's expertise aligns with BerGenBio's focused strategy in conducting Ph1b/2a BGBC016 trials for NSCLC patients with STK11 mutations.
About BerGenBio
Headquartered in Bergen, BerGenBio ASA is dedicated to developing transformative drugs targeting AXL as a potential cornerstone for treating aggressive diseases, including certain cancers and severe respiratory conditions. Their flagship product, bemcentinib, is in development as a selective AXL inhibitor and may represent a significant breakthrough for NSCLC patients with specific mutations.
Looking Ahead
As BerGenBio charts its future, the leadership under Olav Hellebø aims to expand its groundbreaking research while addressing the urgent medical needs that currently exist in oncology treatments. The board believes that Hellebø's strategic insights will bolster BerGenBio's mission and further its innovations in cancer therapy.
Frequently Asked Questions
Who is Olav Hellebø?
Olav Hellebø is the newly appointed CEO of BerGenBio ASA, bringing extensive expertise from the biopharmaceutical industry.
What is BerGenBio's main focus?
BerGenBio focuses on developing selective AXL inhibitors for treating cancers and severe respiratory infections.
What experience does Olav Hellebø have?
He has over 30 years of experience in leadership roles at various biopharmaceutical companies, including directorships and CEO positions.
What is bemcentinib?
Bemcentinib is BerGenBio's lead candidate, designed to be a selective AXL inhibitor aimed at treating specific cancer types.
How does this appointment impact BerGenBio?
Hellebø's appointment is expected to drive the company's strategy forward, particularly in advancing their clinical trials for innovative cancer treatments.
